about
Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney diseaseTriggers, inhibitors, mechanisms, and significance of eryptosis: the suicidal erythrocyte deathDiabetic kidney disease: a report from an ADA Consensus ConferenceSickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Mechanisms of anemia in CKD.Effect of peritoneal dialysis versus hemodialysis on renal anemia in renal in end-stage disease patients: a meta-analysis.Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfate.Reticulocyte-based estimation of red blood cell lifespan.Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.Management of Hyperglycemia in Diabetic Kidney Disease.Association of Estimated Glomerular Filtration Rate with Hemoglobin Level in Korean Adults: The 2010-2012 Korea National Health and Nutrition Examination SurveyErythrocyte glutathione transferase: a new biomarker for hemodialysis adequacy, overcoming the Kt/V(urea) dogma?Alterations of erythrocyte rheology and cellular susceptibility in end stage renal disease: Effects of peritoneal dialysisGlutathione redox potential is low and glutathionylated and cysteinylated hemoglobin levels are elevated in maintenance hemodialysis patients.Models for the red blood cell lifespan.Does the extracorporeal circulation worsen anemia in hemodialysis patients? Investigation with advanced microscopes of red blood cells drawn at the beginning and end of dialysisClinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?Hemoglobin a1c in the ESRD population: status report.Therapeutic potential of manipulating suicidal erythrocyte death.Markers of iron status in chronic kidney disease.Successful creation of an anemia management algorithm for hemodialysis patients.A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease.Suicidal erythrocyte death in end-stage renal disease.Developing a classification system for haemoglobin management in patients with end-stage renal disease on haemodialysis: a secondary data analysis.Haemolysis in haemodialysis.Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease.Ankyrin is the major oxidised protein in erythrocyte membranes from end-stage renal disease patients on chronic haemodialysis and oxidation is decreased by dialysis and vitamin C supplementation.Shortened red blood cell lifespan is related to the dose of erythropoiesis-stimulating agents requirement in patients on hemodialysis.Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
P2860
Q26827458-78BC479D-AD70-4848-BD43-B4B32B25121CQ26852497-F72F71E0-912D-45D6-87B2-FCA4496CF10FQ27012546-CD041A51-2ED3-4B57-8F3E-0E16AF43D559Q27303155-EEE957C4-A442-4123-AA20-3B78E5EBC8DFQ27693202-15D6157C-F9AE-4D96-87D8-6EE12F1C6430Q30241186-BD77C5A9-BBEA-4B98-8306-64BD631D93EFQ31142636-90D61EA0-7741-430D-B170-2A76CA5524DEQ33770094-5CC7DC61-F83D-464F-A2D1-EB851D9456E3Q35944877-F1A29A18-AD54-453D-BDAF-1836F45B78AAQ35953856-65F6CEE5-B668-4DF9-84C3-B634B4C01F85Q36003320-C085B570-0936-41ED-8544-40BEC33DCB35Q36211438-C4470E46-4D1C-42C2-B9FD-A93C053A857FQ36269951-8F157258-ADEB-4CBE-ABD8-B67CB2AE4FA5Q36931755-04D9290E-0965-4771-88D7-C4276B7BE406Q36952011-869636CC-28E5-4C04-93F3-C558E2214F3AQ37233333-92DAEAA8-F0CA-4006-AED1-E350D4788DA3Q38126361-44A63F50-E80D-4C43-989A-3F8DBAEF2415Q38182542-B2ADA877-81C7-4CB8-9086-F37578F1167BQ38231450-428102DD-BBAA-455D-A1F3-FFDD0432D0F8Q38503447-5886EF5C-CD8E-4AB3-B9C1-49397854B5F5Q38887263-E68B8C5A-A458-4FF3-9B81-0082DD58D42CQ41621194-66CE4237-76A9-4A28-B24A-D840EFE1F1C2Q41808839-B51F09E5-6F62-4D2A-9D8A-21BA9BD448ECQ46904253-E8629764-60FC-424A-AEE7-46B1C824EE09Q47100475-B5FE8D71-A2D8-4CC8-8E15-04EE50860015Q47819838-6BCD0E6C-FD74-4CF6-B8E9-5067B0C293EDQ48157066-89EA2717-B0CD-460C-8657-04B5CA9928FFQ50456717-713C6D57-2719-468C-A701-7D9706943736Q50499724-D23335BC-15A6-4FC0-A756-544298EFC55EQ50527011-64A03D9A-2D3F-4D6D-A856-F90DA59C8BF8Q53823548-0E09EB4B-05C3-4993-B7C3-552E77E15553
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Red blood cell survival in long-term dialysis patients.
@en
Red blood cell survival in long-term dialysis patients.
@nl
type
label
Red blood cell survival in long-term dialysis patients.
@en
Red blood cell survival in long-term dialysis patients.
@nl
prefLabel
Red blood cell survival in long-term dialysis patients.
@en
Red blood cell survival in long-term dialysis patients.
@nl
P2093
P1476
Red blood cell survival in long-term dialysis patients
@en
P2093
Carolyn V Coulter
Frederiek E Vos
John B Schollum
Robert J Walker
Terrence C A Doyle
P304
P356
10.1053/J.AJKD.2011.03.031
P577
2011-06-29T00:00:00Z